EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Belzutifan for Advanced Pheochromocytoma or Paraganglioma

Camilo Jimenez, Mikkel Andreassen, Alice Durand, Sophie Moog, Andrew Hendifar, Staffan Welin, Francesca Spada, Rohini Sharma, Edward Wolin, Joseph Ruether, Rocio Garcia-Carbonero, Martin Fassnacht iD und 14 weitere

New England Journal of Medicine · 20.11.2025 · 393 (20) · 2012-2022

DOI: 10.1056/nejmoa2504964 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 20.11.2025. Verfasst von Camilo Jimenez und 25 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas M.D. Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Adrenal Gland Neoplasms, Antineoplastic Agents, Pheochromocytoma, Indenes. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Merck Sharp and Dohme, MSD Sharp and Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pheochromocytoma and paraganglioma are neoplasms originating in the adrenal medulla and extraadrenal paraganglia, respectively. Most cases of metastatic pheochromocytoma and paraganglioma are driven by dysregulation of the hypoxia-inducible factor 2α (HIF-2α) pathway. Belzutifan is a HIF-2α inhibitor that may provide antitumor activity in patients with advanced pheochromocytoma or paraganglioma. METHODS: We conducted a phase 2, international, single-group trial involving 72 participants with locally advanced or metastatic pheochromocytoma or paraganglioma that was not amenable to surgery or curative-intent treatment. Participants received belzutifan at a dose of 120 mg once daily until the occurrence of progression, unacceptable toxic effects, or withdrawal from the trial. The primary end point was confirmed objective response (complete or partial response) as assessed by blinded independent central review. Secondary and other key end points included the duration of response, disease control, progression-free survival as assessed by blinded independent central review, overall survival, safety, and a reduction from baseline in antihypertensive medication. RESULTS: At a median follow-up of 30.2 months (range, 23.3 to 37.6), the percentage of participants with a confirmed objective response was 26% (95% confidence interval [CI], 17 to 38) and the percentage of participants with disease control was 85% (95% CI, 74 to 92). The median duration of response was 20.4 months (95% CI, 8.3 to not reached), with a median duration of progression-free survival of 22.3 months (95% CI, 13.8 to not reached). Overall survival was 76% at 24 months. Among the 60 participants who were receiving antihypertensive medications, 19 (32%) had a reduction of at least 50% in the total daily dose of at least one antihypertensive medication for at least 6 months after starting treatment with belzutifan. Treatment-related adverse events occurred in 71 participants (99%); anemia of grade 3 was noted in 22% of the participants. Eight participants (11%) had treatment-related serious adverse events. CONCLUSIONS: Belzutifan showed antitumor activity with durable responses in participants with advanced pheochromocytoma or paraganglioma. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; LITESPARK-015 ClinicalTrials.gov number, NCT04924075.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Gland NeoplasmsAntineoplastic AgentsPheochromocytomaIndenesParaganglioma, Extra-AdrenalAdultAgedFemaleHumansMaleMiddle AgedYoung AdultProgression-Free SurvivalFollow-Up StudiesAntihypertensive AgentsAnemiaHypertension

Substanzen

Antineoplastic AgentsbelzutifanIndenesAntihypertensive Agents

Autor:innen und Institutionen

  • University of Texas M.D. Anderson Cancer Center, Houston.
  • Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen.
  • Department of Medical Oncology, Hôpital Edouard Herriot, Lyon, France.
  • Endocrine Oncology Unit, Gustave Roussy, Villejuif, France.
  • Cedars-Sinai Medical Center, Los Angeles.
  • Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.

ORCID-Profile: Martin Fassnacht

Förderung

  • Merck Sharp and Dohme
  • MSD Sharp and Dohme

Zitieren

APA

Jimenez, C., Andreassen, M., Durand, A., Moog, S., Hendifar, A., Welin, S., Spada, F., Sharma, R., Wolin, E., Ruether, J., Garcia-Carbonero, R., Fassnacht, M., Capdevila, J., Del Rivero, J., Iliopoulos, O., Huillard, O., Jang, R., Mai, K., Artamonova, E., …, & LITESPARK-015 Investigators (2025). Belzutifan for Advanced Pheochromocytoma or Paraganglioma. New England Journal of Medicine, 393(20), 2012-2022. https://doi.org/10.1056/nejmoa2504964

Vancouver

Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, et al. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. New England Journal of Medicine. 2025;393(20):2012-2022. doi:10.1056/nejmoa2504964

BibTeX
@article{Jimenez2025,
  author = {Jimenez, Camilo and Andreassen, Mikkel and Durand, Alice and Moog, Sophie and Hendifar, Andrew and Welin, Staffan and Spada, Francesca and Sharma, Rohini and Wolin, Edward and Ruether, Joseph and Garcia-Carbonero, Rocio and Fassnacht, Martin and Capdevila, Jaume and Del Rivero, Jaydira and Iliopoulos, Othon and Huillard, Olivier and Jang, Raymond and Mai, Knut and Artamonova, Elena and Hallqvist, Andreas and Else, Tobias and Odeleye-Ajakaye, Amos and Gozman, Alexander and Naik, Girish S and Berruti, Alfredo and LITESPARK-015 Investigators, LITESPARK-015 Investigators},
  title = {Belzutifan for Advanced Pheochromocytoma or Paraganglioma},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {20},
  pages = {2012--2022},
  doi = {10.1056/nejmoa2504964}
}
Kostenlos starten →